Our catalog now includes SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent article to display neutralizing activity against SARS-CoV-2, the coronavirus that causes COVID-19. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Binding curve of anti-spike protein (RBD) antibody CV30 (Ab02019-1.1) to SARS-CoV-2 spike protein RBD-Fc fusion protein. ELISA plate was coated with SARS-CoV-2 spike protein RBD-Fc rabbit fusion protein (Pr00444; Absolute Antibody) at a concentration of 2.5 µg/ml. A 3-fold serial dilution from 1,000 ng/ml was performed using a mouse IgG1 antibody Ab02019-1.1-HRP.
Available formats include:
- Human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests
- Species such as mouse and rabbit for detection applications and co-labeling studies
- Fragment formats for better tissue penetration and in vivo imaging
- Engineered Fc Silent™ domains to facilitate research into antibody-dependent enhancement
As with all Absolute Antibody reagents, the new antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels. Learn more about each clone by following the links below.
|Clone Name||Catalog Number|
|Anti-Spike Protein [CV1]||Ab02018|
|Anti-Spike Protein (RBD) [CV30]||Ab02019|
The new neutralizing antibodies join our full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests. Contact us with any questions or to request a quote.
hubXchange | Antibody Therapeutics USA West
20th September 2022
San Fransisco, CA